Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

When there are higher than normal amounts of HER2 on breast cancer cells, the cancer is called HER2 positive. And these cancer cells can grow more rapidly than other breast cancers. HER2 positive ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy.

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing your disease, not curing the cancer. The goal is to help you live longer and have a better ...